The Analysis Of The Curative Effect Of Zoledronic Acid In Treating Nonmetastatic Prostate Cancer Patients With Bone Density Reduce Caused By ADT

Objective: To analyses and evaluate the curative effect of zoledronic acid intreating nonmetastatic prostate cancer patients with bone density reduce caused by ADT.Methods and Materials: With23pathology confirmed prostate cancerpatients,Gleason6~9,TNM staging T3and above. All the patients had never received radical prostatectomy (refused to the radical prostatectomy or does not meet theindications) but received maximal androgen blockade for more than2years. All thepatients have a follow-up no less than24months and detected on medical iconography,no evidence of metastasis had been found. All the patients test the baseline BMD,-1.0≥T＞-2.5，had never used medicine or food which influence bone metabolism.Exclusion criteria: primary gonad hypofunction、thyroid function hyperfunction、hyperparathyroidism、 cushing syndrome、 longtime using of steroid hormone、osteoarticular diseases（metabolic bone diseaseankylosing arthritis，et al）、follow-updata missing and Tumor metastasis.14patients accepted zoledronic acid4mg ivmonthly, and with5%glucose and sodium chloride injection iv before dose. The controlgroup has the other9patients who refused to the zoledronic acid therapy (for economicproblems、personal willingness，et al) and only gave5%glucose and sodium chlorideinjection iv monthly. Test BSAP、ICTP and N-Mid-Osteocalcin at the time point of6、12、24month and measure the BMD (left front arm) at the time point of12、24monthafter the research started. Use the t test to estimate the data differences between the2groups.Results: The left front arm BMD reduced4.87%in the control group while thetreatment group reduced3.2%at12month(P=0.36);14.12%were reduced in the controlgroup and7.08%were reduced in the treatment group at24month(P=0.049).At6month, the increase of BSAP、Osteocalcin and ICTP in the control and treatment groupwere28.00%、63.96%、106.1%；3.57%、21.05%、1.70%respectively. Only the ICTPbetween the2groups was statistical difference (P=0.003).But at12and24month,allthe3indicators has significant statistical differences.Conclusion:The treatment of zoledronic acid（4mg,monthly iv）can prevent the loss of BMDcaused by ADT、reduce the bone absorption and it can prevent bone mineral loss andosteoporosis to some extent.